This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-EDB scFv to IL10. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the EDB as well as the biological activity of IL10. The fusion protein L19-IL10 displayed a therapeutic activity, which was superior to the activity of IL10 fused to an antibody of irrelevant specificity in the mouse. The fusion protein L19-IL10 might help overcome some of the clinical limitations of IL10 and provide a therapeutic benefit to patients with chronic inflammatory disorders, including arthritis. This immunocytokine was designed for treating Advanced solid tumors, Advanced pancreatic cancer, Metastatic melanoma.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-001CQ | Anti-Human FN1 Recombinant Antibody (MOR03255) | ELISA, Block, IHC | Human antibody |
TAB-002CQ | Anti-Human FN1 Recombinant Antibody (ME-4C) | ELISA, IHC | Human antibody |
TAB-003CQ | Anti-Human FN1 Recombinant Antibody (1C5) | ELISA, WB | Human antibody |
TAB-004CQ | Human Anti-FN1 Recombinant Antibody (TAB-004CQ) | ELISA, IHC, WB | Human IgG |
TAB-001CQ-S(P) | Anti-Human FN1 Recombinant Antibody scFv Fragment (MOR03255) | ELISA, BL, IHC | Human antibody |
There are currently no Customer reviews or questions for ACFP-SH085. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.